{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:39:53Z","timestamp":1787668793749,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0296"],"award-info":[{"award-number":["W81XWH-21-1-0296"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA271540"],"award-info":[{"award-number":["1R01CA271540"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA273956"],"award-info":[{"award-number":["U54CA273956"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA231776"],"award-info":[{"award-number":["U01CA231776"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA212007"],"award-info":[{"award-number":["U01CA212007"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018771","name":"Veracyte Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.04.009","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T03:54:09Z","timestamp":1752724449000},"page":"968-976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology\/RTOG 0521 Phase 3 Trial"],"prefix":"10.1016","volume":"8","author":[{"given":"Ryan M.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff M.","family":"Simko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Den","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Longoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Straza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.04.009_b0005","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.04.009_b0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijrobp.2015.05.024","article-title":"A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of Radiation Therapy Oncology Group phase 3 randomized trial NRG Oncology RTOG 9902","volume":"93","author":"Rosenthal","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.04.009_b0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.04.009_b0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2023.04.024","article-title":"Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: long-term follow-up from the randomized NRG Oncology RTOG 0521 trial","volume":"84","author":"Sartor","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.04.009_b0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac043","article-title":"Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial","volume":"6","author":"James","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.euo.2025.04.009_b0045","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1200\/JCO.2006.08.4152","article-title":"Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202","volume":"25","author":"Chakravarti","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0050","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1470-2045(07)70280-2","article-title":"COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial","volume":"8","author":"Khor","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0055","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1158\/1078-0432.CCR-06-2972","article-title":"Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02","volume":"13","author":"Khor","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.009_b0060","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2008.19.8267","article-title":"MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02","volume":"27","author":"Khor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0065","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1158\/1078-0432.CCR-08-2704","article-title":"The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02","volume":"15","author":"Pollack","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.009_b0070","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/1078-0432.CCR-14-0075","article-title":"A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02","volume":"20","author":"Pollack","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.04.009_b0075","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/pcan.2016.58","article-title":"Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer","volume":"20","author":"Nguyen","year":"2017","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euo.2025.04.009_b0080","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2025.04.009_b0090","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.170182","article-title":"Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?","volume":"7","author":"Mitchison","year":"2017","journal-title":"Open Biol"},{"key":"10.1016\/j.euo.2025.04.009_b0095","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.annonc.2021.06.003","article-title":"Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial","volume":"32","author":"Hamid","year":"2021","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.euo.2025.04.009_b0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.2018.36.6_suppl.197","article-title":"Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications","volume":"36","author":"Kim","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.04.009_b0105","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.04.009_b0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG Oncology\/Radiation Therapy Oncology Group 9202, 9413, and 9902 phase 3 randomized trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.04.009_b0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/biostatistics\/kxt050","article-title":"Predicting the restricted mean event time with the subject\u2019s baseline covariates in survival analysis","volume":"15","author":"Tian","year":"2014","journal-title":"Biostatistics"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:26:31Z","timestamp":1762629991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001038"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology\/RTOG 0521 Phase 3 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}